<DOC>
	<DOCNO>NCT02507570</DOCNO>
	<brief_summary>This open label study design examine effect Enzalutamide concurrent administration Radium Ra 223 dichloride Castrate-Resistant ( Hormone-Refractory ) Prostate Cancer subject symptomatic bone metastases pre- post-chemotherapy setting .</brief_summary>
	<brief_title>Open Label Phase Two Study Enzalutamide With Concurrent Administration Radium Ra 223 Dichloride Castration-Resistant ( Hormone-Refractory ) Prostate Cancer Subjects With Symptomatic Bone Metastasis</brief_title>
	<detailed_description>This open label study design examine effect Enzalutamide concurrent administration Radium Ra 223 dichloride castrate resistant ( hormone-refractory ) prostate cancer subject symptomatic bone metastasis , pre- post- chemotherapy setting . Radium Ra 223 dichloride approve US Food Drug Administration indication . Enzalutamide US Food Drug Administration approve indication . Approximately 40 subject enrol obtain 30 evaluable subject . All subject receive Radium Ra 223 dichloride every 4 week total 6 dos 24 week concurrent Enzalutamide minimum duration 24 week . The sponsor provide Enzalutamide End Treatment visit last Long Term Follow Up visit complete . Subjects continue receive Enzalutamide long positive response therapy demonstrate . Enzalutamide may discontinue time per physician discretion . Subjects evaluate 30 day last dose Radium Ra 223 dichloride . Including screening , total duration study 32 week plus every 3 month follow visit subject receive Enzalutamide .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Eligible subject conform inclusion criterion list : 1 . Subject must able understand willing sign write Informed Consent Form . A signed IRB approve Informed Consent Form must appropriately obtain prior conduct studyspecific procedure . 2 . Subject willing able comply protocol , include study visit procedure . 3 . Subject male , great 18 year time enrollment . 4 . Life expectancy least 9 month . 5 . Subject histologically documented prostate cancer confirm pathology report prostate biopsy radical prostatectomy specimen . 6 . Subject must : 1. initiate stable dose daily Enzalutamide within 45 day enrollment ( Cycle 1/Week 1/ Day 1 ) , 2. plan initiate stable daily dose Enzalutamide within 30 day first Radium Ra 223 dichloride treatment . 7 . Subject must plan receive 6 Radium Ra 223 dichloride injection daily oral dos Enzalutamide study , per protocol . 8 . Subject history bone metastasis prostate cancer evidence image perform within 90 day enrollment ( Cycle 1/Week 1/Day 1 ) one following : 1 . Tc Bone Scan 2 . Sodium Fluoride PET/CT Scan If bone scan use , solitary lesion could contribute cause prostate cancer must confirm second modality ( i.e . : plain film , CT scan MRI ) . 9 . Subject Castrate Resistant Prostate Cancer , define rise PSA level testosterone level &lt; /= 50ng/dl ( 2.0 nM/L ) receive androgen deprivation therapy ( medical surgical castration ) . Subject must also plan receive androgen deprivation therapy throughout study . PSA progression define least 2 rise PSA level take least 7 day apart , 2nd PSA 2.0 ng/dl great . 10 . Subject presence cancer relate bone pain require treatment analgesic medication ( include limit acetaminophen , NSAIDS , Cox2 inhibitor , narcotic opioids ) . 11 . Subject ECOG performance status 02 screen enrollment visit . 12 . Acceptable hematology serum biochemistry screen value : White Blood Cell ( WBC ) &gt; /= 3,000/mm3 Absolute Neutrophil Count ( ANC ) &gt; 1500/mm3 Platelet ( PLT ) count &gt; 100,000/mm3 Hemoglobin ( HGB ) &gt; 10.0 g/dL ( 100g/L ; 6.2 mmol/L Creatinine &lt; 1.5 ULN Total bilirubin level &lt; 1.5 X ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 X ULN albumin &gt; 25 g/L Baseline electrolytes within normal limit ( Sodium , potassium , chloride , calcium , phosphate , magnesium , LDH , Î³GT , urea , total protein ) 13 . Normal Liver Function Tests ( LFT ) normal Renal Function Tests ( RFT ) screen visit . If subject LFT 's RFT 's great 2.5 time upper limit normal ( ULN ) , Medical Monitor review , conjunction subject 's PI , require . 14 . Subjects receive AntiResorptive medication , denosumab ( XGEVA ) Zolendronic Acid ( Zometa ) , must stable dose least 90 day prior enrollment ( Cycle 1/Week 1/Day 1 ) . Antiresorptive medication may add subject 's regimen study . Antiresorptive discontinuation allow per Investigator discretion due adverse event attributable medication . 15 . Subjects childbearing potential must agree use adequate contraception begin enrollment least 30 day last dose study drug . The definition adequate contraception base judgment principal investigator designate associate . Eligible subject must meet exclusion criterion list : 1 . Subject know malignant pleural effusion , know lung , liver brain metastasis ( lymph node metastasis &lt; 6 cm shortaxis diameter allow ) . 2 . Subject history seizure condition may predispose seizure ( e.g . prior cortical stroke , significant brain trauma ) time past , history loss consciousness transient ischemic attack within 12 month enrollment ( Cycle 1/Week 1/Day 1 ) . 3 . Subject receive previous treatment Enzalutamide longer 45 day prior enrollment ( Cycle 1/Week 1/Day 1 ) , prior treatment Radium Ra 223 dichloride . 4 . Subject know medical contraindication Enzalutamide Radium Ra 223 dichloride . 5 . Subject willing initiate stable dose daily Enzalutamide within 45 day enrollment ( Cycle 1/Week1/Day 1 ) , plan initiate stable daily dose Enzalutamide within 30 day first Radium Ra 223 dichloride treatment ( Cycle 1/Week 1/Day 1 ) . 6 . Subject plan receive 6 injection Radium Ra 223 Dichloride daily Enzalutamide study , per protocol . 7 . Subject receive previous strontium89 , samarium153 , rhenium186 , rhenium188 treatment bone metastasis within 24 week prior enrollment ( Cycle 1/Week 1/Day 1 ) . 8 . Subject receive denosumab Zolendronic Acid le 90 day prior enrollment ( Cycle 1/Week 1/Day 1 ) , subject plan discontinue antiresorptive prior End Treatment visit last Long Term Follow Up visit . 9 . Subject receive investigational product experimental therapy within 4 week enrollment ( Cycle 1/Week 1/Day 1 ) , initiation either plan prior End Treatment visit last Long Term Follow Up visit . 10 . Subject treatment cytotoxic chemotherapy within 4 week enrollment ( Cycle 1/Week 1/Day 1 ) , plan prior End Treatment visit last Long Term Follow Up visit , failure recover adverse event due cytotoxic chemotherapy administer 4 week prior enrollment ( Cycle 1/Week 1/Day 1 ) , persistent myelosuppression , GI toxicity , severe fatigue . Ongoing neuropathy exclusionary . 11 . Subject history severe liver insufficiency ( r ChildPugh class B C ) . 12 . Subject history myocardial infarction cardiac arrhythmia within 6 month prior enrollment ( Cycle 1/Week 1/ Day 1 ) . 13 . Subject history previous radiotherapy &gt; 25 % bone marrow , include hemibody radiation . 14 . Subject history malignancy within previous 5 year . A history squamous basal cell carcinoma lowgrade superficial bladder cancer adequately treat least 12 month prior enrollment exclusionary . 15 . Subject undergone major surgery within 4 week prior enrollment ( Cycle 1/Week 1/Day 1 ) . 16 . Subject blood transfusion erythropoietin stimulation agent within 4 week enrollment ( Cycle 1/Week 1/Day 1 ) . 17 . Subject know imminent establish spinal cord compression . 18 . Subject serious concurrent medical condition psychiatric illness . 19 . Subject history serious illness medical condition include , limited uncontrolled infection , congestive heart failure New York Heart Association ( NYHA ) class III IV , Crohn 's Disease Ulcerative Colitis , uncontrolled hypertension Bone Marrow Dysplasia screen . 20 . Subject gastrointestinal disorder affect absorption ( e.g . gastrectomy , active peptic ulcer disease within 90 day prior enrollment ( Cycle 1/Week 1/Day 1 ) 21 . Subject able swallow study treatment capsule . 22 . Subject unmanageable fecal incontinence . 23 . Subject condition , opinion investigator , would impair patient 's ability comply study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>